Related references
Note: Only part of the references are listed.High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma
Yun Hou et al.
MEDICAL ONCOLOGY (2012)
Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Weiguo Hu et al.
CANCER RESEARCH (2011)
Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells
Tao You et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2011)
rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
Xiaowen Ge et al.
CLINICAL CANCER RESEARCH (2011)
New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice
Jonathan W. Friedberg
CLINICAL CANCER RESEARCH (2011)
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy
Hongjie Wang et al.
BLOOD (2010)
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP
Jesse Shustik et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era
Mariano Provencio et al.
LEUKEMIA & LYMPHOMA (2010)
Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin's lymphoma
Justyna Dzietczenia et al.
MEDICAL ONCOLOGY (2010)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mechanism of action and resistance to monoclonal antibody therapy
N Villamor et al.
SEMINARS IN ONCOLOGY (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Tissue microarrays for rapid linking of molecular changes to clinical endpoints
J Torhorst et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
WK Weng et al.
BLOOD (2001)
Validation of tissue microarray technology in breast carcinoma
RL Camp et al.
LABORATORY INVESTIGATION (2000)
Share Paper
